Cargando…

A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30(+) tumor cells

To improve recruitment and activation of natural killer (NK) cells to lyse tumor cells, we isolated a human anti-CD16A antibody with similar affinity for the CD16A 158F/V allotypes, but no binding to the CD16B isoform. Using CD16A-targeting Fv domains, we constructed a tetravalent bispecific CD30/CD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reusch, Uwe, Burkhardt, Carmen, Fucek, Ivica, Le Gall, Fabrice, Le Gall, Mikaelle, Hoffmann, Karin, Knackmuss, Stefan HJ, Kiprijanov, Sergej, Little, Melvyn, Zhukovsky, Eugene A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2014
Materias:	Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4011917/ https://www.ncbi.nlm.nih.gov/pubmed/24670809 http://dx.doi.org/10.4161/mabs.28591

Ejemplares similares

Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies
por: Ellwanger, Kristina, et al.
Publicado: (2017)

EGFRvIII TandAbs are specific and highly potent drug candidates for the treatment of solid tumors
por: Ellwanger, Kristina, et al.
Publicado: (2015)

Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor d-1-methyl-tryptophan
por: Zhang, Xiaolong, et al.
Publicado: (2017)

AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
por: Wu, Jingjing, et al.
Publicado: (2015)

Development of a Bispecific Antibody Targeting CD30 and CD137 on Hodgkin and Reed-Sternberg Cells
por: Rajendran, Sakthi, et al.
Publicado: (2019)

Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activity
por: Faber, Mary L., et al.
Publicado: (2023)

CD30-Positive Extracellular Vesicles Enable the Targeting of CD30-Negative DLBCL Cells by the CD30 Antibody-Drug Conjugate Brentuximab Vedotin
por: Lobastova, Liudmila, et al.
Publicado: (2021)

Brentuximab Vedotin in CD30+ Lymphomas
por: Perini, Guilherme Fleury, et al.
Publicado: (2013)

Characterization of CD30/CD30L(+) Cells in Peripheral Blood and Synovial Fluid of Patients with Rheumatoid Arthritis
por: Barbieri, Alessandro, et al.
Publicado: (2015)

Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30(+) lymphoma patients
por: Wang, D., et al.
Publicado: (2020)

Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas
por: Tschernia, Nicholas P, et al.
Publicado: (2023)

Skin CD30(+) T cells and circulating levels of soluble CD30 are increased in patients with graft versus host disease
por: Amedei, Amedeo, et al.
Publicado: (2013)

High soluble CD30, CD25 and IL-6 may identify patients with worse survival in CD30+ cutaneous lymphomas and early mycosis fungoides
por: Kadin, Marshall E., et al.
Publicado: (2011)

Diffuse skin hyperpigmentation in CD30+ lymphoproliferation
por: Prka, Zeljko, et al.
Publicado: (2012)

CD30 expression by CD8+ T cells producing type 2 helper cytokines. Evidence for large numbers of CD8+CD30+ T cell clones in human immunodeficiency virus infection
Publicado: (1994)

Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30(+) lymphoma
por: Zhang, Peiling, et al.
Publicado: (2022)

CD3+, CD56+, CD4−, CD8−, CD20−, CD30− Peripheral T-Cell Non-Hodgkin's Lymphoma: A Rare Case Report
por: Jagati, Ashish, et al.
Publicado: (2017)

TB granuloma: CD30 co-stimulation for CD4(+) T cell co-operation
por: Gress, Abigail R., et al.
Publicado: (2023)

Elevated ATP via enhanced miRNA-30b, 30c, and 30e downregulates the expression of CD73 in CD8(+) T cells of HIV-infected individuals
por: Shahbaz, Shima, et al.
Publicado: (2022)

Single-Fraction Radiotherapy for CD30(+) Lymphoproliferative Disorders
por: Gentile, Michelle S., et al.
Publicado: (2015)

Brentuximab vedotin: targeting CD30 as standard in CTCL
por: Prince, H. Miles, et al.
Publicado: (2018)

CD30(+) lymphomatoid skin toxicity secondary to ipilimumab
por: Bush, Amelia E., et al.
Publicado: (2020)

The Polyvalent Role of CD30 for Cancer Diagnosis and Treatment
por: Dumitru, Adrian Vasile, et al.
Publicado: (2023)

Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors
por: Wingert, Susanne, et al.
Publicado: (2021)

Levels of Soluble CD30 and CD26 and Their Clinical Significance in Patients with Primary Immune Thrombocytopenia
por: Wang, Honghui, et al.
Publicado: (2020)

CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin’s Lymphoma
por: Xue, YuanBo, et al.
Publicado: (2021)

CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro
por: Hansen, Hinrich P., et al.
Publicado: (2016)

Conjugation of DM1 to anti-CD30 antibody has potential antitumor activity in CD30-positive hematological malignancies with lower systemic toxicity
por: Shen, Yijun, et al.
Publicado: (2019)

A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb
por: Wu, Yang, et al.
Publicado: (2021)

Anti-CD22/CD20 Bispecific Antibody with Enhanced Trogocytosis for Treatment of Lupus
por: Rossi, Edmund A., et al.
Publicado: (2014)

Study of the expression of CD30 in pterygia compared to healthy conjunctivas
por: Garfias, Yonathan, et al.
Publicado: (2009)

Challenges of driving CD30-directed CAR-T cells to the clinic
por: Grover, Natalie S., et al.
Publicado: (2019)

Better method for detection of CD30: Immunohistochemistry or flow cytometry?
por: Higashi, Morihiro, et al.
Publicado: (2021)

Genomic Analysis of Cutaneous CD30-Positive Lymphoproliferative Disorders
por: Abdulla, Farah R., et al.
Publicado: (2021)

Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed/Refractory CD30+ Lymphoma
por: Sang, Wei, et al.
Publicado: (2022)

Effect of HIV infection on the expression and the activity of the proteasome in primary CD4 T cells
por: Boucau, J, et al.
Publicado: (2012)

Latency reversal agents modulate HIV antigen processing and presentation to CD8 T cells
por: Boucau, Julie, et al.
Publicado: (2020)

A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells
por: Bühler, P., et al.
Publicado: (2007)

Targeting immunotherapy for bladder cancer by using anti-CD3 × CD155 bispecific antibody
por: Ma, Wanru, et al.
Publicado: (2019)

Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting
por: Mhibik, Maissa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_niftrr7guo0n8c93mv0bqrg8oo